Brief: Medincell H1 Operating Loss Widens To EUR 11.2 Mln

Medincell SA

08/12/2021 17:33

Dec 8 (Reuters) - MEDINCELL SA  MEDCL.PA :
    * MEDINCELL PUBLISHES ITS FINANCIAL RESULTS AND ACTIVITY
REPORT
FOR THE FIRST HALF OF 2021-2022 (APRIL - SEPTEMBER 2021)
    * H1 REVENUE: EUR 4.1 MLN (+30% COMPARED WITH FIRST HALF OF
PREVIOUS YEAR)
    * H1 OPERATING EXPENSES: EUR 15.3 MLN (+36%)
    * END-H1 AVAILABLE CASH: EUR 34.4 MILLION IN CASH + EUR 3.0
MILLION IN NON-RISKY FINANCIAL ASSETS (EUR 2.9 MILLION CURRENT +
EUR 0.1 MILLION NON-CURRENT)
    * MDC-IRM (SCHIZOPHRENIA): MARKETING PLANNED FROM 2022 BY
TEVA IN
UNITED STATES, SUBJECT TO FDA APPROVAL
    * POINTS OUT THAT FIRST REVENUES LINKED TO PRODUCT SALES
SHOULD BE
ROYALTIES FROM MARKETING OF FIRST PRODUCT DEVELOPED WITH TEVA
PHAMACEUTICAL
    * H1 FINANCIAL LOSS EUR 0.5 MILLION VERSUS LOSS EUR 2.6
MILLION
YEAR AGO
    * H1 OPERATING LOSS EUR 11.2 MILLION VERSUS LOSS EUR 8.2
MILLION
YEAR AGO

Source text for Eikon:  ID:nBw1nPpGza 
Further company coverage:  MEDCL.PA 

 (Gdansk Newsroom)
 ((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))